| Target Price consensus revisions : last 18 months |
|
|
|
| Evolution of the average Target Price on NOVARTIS AG |
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Novartis : buys neuroscience company Cadent for up to $770 million |
|
NOVARTIS AG
Back to basics |
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
25 |
| Average target price |
109,54 $ |
| Last Close Price |
97,04 $ |
| Spread / Highest target |
53,4% |
| Spread / Average Target |
12,9% |
| Spread / Lowest Target |
-7,00% |
Consensus revision (last 18 months)
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
